The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC).
 
Ali Raza Khaki
Stock and Other Ownership Interests - Merck; Sanofi
 
Yong Shan
No Relationships to Disclose
 
Richard Nelson
No Relationships to Disclose
 
Sapna Kaul
No Relationships to Disclose
 
John L. Gore
Research Funding - Ferring
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genentech; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Kure It Cancer Research (Inst); Merck (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Stephen B. Williams
Consulting or Advisory Role - Photocure; Taris BioMedical (Inst); UroToday
Travel, Accommodations, Expenses - Janssen